Synthesize Bio

Synthesize Bio is an AI-driven virtual human modeling company that develops generative genomics foundation models to predict how human tissues and cells respond to drugs, diseases, and biological perturbations. Built on the largest consistently normalized and annotated RNA-seq corpus ever assembled, the platform enables biopharma teams to describe experiments in natural language and receive lab-quality bulk and single-cell RNA-seq data grounded in real human biology.

The company actively partners with biopharma organizations to deploy these capabilities across therapeutic pipelines and clinical development programs, helping teams iterate faster, test more broadly, and make more confident drug development decisions at every stage.

Core Platform: GEM-1 Foundation Model

• GEM-1 is a generative genomics foundation model that predicts human tissue responses to therapeutic interventions by producing lab-quality bulk and single-cell RNA-seq data from natural-language experimental descriptions.
• Trained on the largest well-annotated and consistently normalized RNA-seq corpus ever assembled, ensuring predictions are grounded in real human biology.
• A public version of the model is available for users to simulate a wide range of experiments based on their own experimental descriptions.
• For clinical applications and proprietary datasets, Synthesize Bio offers dedicated partnership engagements.
• Full model architecture, validation standards, and data harmonization methodology are detailed in a published preprint.

Clinical Trial Augmentation and Trial Design

• Extends small Phase 1/2 cohorts with synthetic patients matched to real trial profiles, enabling teams to test endpoints, refine stratification, and model dose-response relationships before committing to large pivotal studies.
• Supports in silico testing of trial designs before protocol lock, allowing teams to model patient responses across enrollment criteria and diverse genetic backgrounds.
• Helps refine inclusion and exclusion criteria, identify patient subgroups most likely to benefit, and explore endpoint strategies to de-risk pivotal trials early.
• Enables rescue of insights from failed or negative trials by augmenting limited datasets, identifying responder subgroups, generating hypotheses for follow-up studies, and building evidence for alternative indications.

Human Tissue Response Prediction and Safety

• Predicts transcriptional responses across multiple human tissue types to surface off-target effects and tissue toxicities that preclinical models may miss.
• Helps anticipate adverse events, prioritize safety biomarkers, and design monitoring strategies before signals emerge in clinical trials.
• Validates mechanism of action in human tissues prior to committing to expensive studies, focusing resources on paths with the strongest biological rationale.
• Maps gene expression profiles across species to validate animal model findings and improve translational success, reducing the risk of preclinical candidates failing in human trials.

Biomarker Discovery and Rare Disease Applications

• Transforms underpowered rare disease datasets into actionable intelligence by generating synthetic cohorts that expand sample sizes while preserving the biological characteristics of limited patient populations.
• Accelerates biomarker discovery by generating gene expression profiles across patient subpopulations and disease states before large clinical studies are initiated.
• Enables testing of stratification hypotheses, refinement of companion diagnostics, and design of enrichment trials with greater confidence.

Data Sharing and Synthetic Cohort Capabilities

• Facilitates cross-organizational collaboration using synthetic cohorts that mirror real patient data without containing patient-identifying information, removing HIPAA-related friction from data sharing.
• Offers access to the SYNTH-cancer database, comprising over 10,000 AI-simulated samples spanning 27 cancer types.

Target Users

• Clinical Development Teams: De-risk trial design, identify predictive biomarkers, stratify patients by response likelihood, and extend early-phase data to inform pivotal trial decisions.
• Drug development teams broadly seeking to accelerate timelines, reduce late-stage failures, and make better-informed development choices across the pipeline.

Synthesize Bio is actively engaging with biopharma partners to deploy its generative genomics capabilities at scale, offering both a publicly accessible model for exploratory experimentation and tailored partnership arrangements for clinical and proprietary applications.